Entered an exclusive license agreement with Edesa Biotech for the development and commercial rights in Japan for EB05, an ARDS therapeutic candidate. Upfront payment of 12 million USD, milestone payments up to 134 million USD, and tiered royalties established. KYORIN will be responsible for clinical trials in Japan. The upfront payment is expected to be recorded in consolidated results for the fiscal year ending March 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"KYORIN Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4569-20261109-04.pdf","jir_short_summary":"Entered an exclusive license agreement with Edesa Biotech for the development and commercial rights in Japan for EB05, an ARDS therapeutic candidate. Upfront payment of 12 million USD, milestone payments up to 134 million USD, and tiered royalties established. KYORIN will be responsible for clinical trials in Japan. The upfront payment is expected to be recorded in consolidated results for the fiscal year ending March 2027.","jir_summary":"### Transaction Overview\nKYORIN Pharmaceutical Co., Ltd. has entered into a license agreement to acquire exclusive rights for the development and commercialization in Japan of EB05, an ARDS therapeutic candidate from Edesa Biotech. An upfront payment of 12 million USD will be made, and milestone payments up to 134 million USD will be payable from development through drug price listing. Tiered royalties based on net sales are also established. KYORIN will be responsible for conducting clinical trials in Japan and aims for product launch.\n\n### Impact and Future Developments\nThis agreement advances the mid-term plan to expand the development pipeline through proactive investment in in-licensing. The upfront payment will be recorded as research and development expense in the consolidated results for the fiscal year ending March 2027. EB05 is an antibody therapy targeting TLR4 intended to improve survival in ARDS. Future development progress and publication of clinical data will be closely watched.","jir_financial_highlights":"Upfront Payment: 12 million USD (Unknown)\nMilestone Payments: up to 134 million USD (Unknown)\nRoyalties Based on Net Sales: Tiered royalties (Unknown)\nScope \/ Impact: Acquisition of exclusive rights for development and commercialization in Japan (Unknown)","jir_category":"","jir_hashtags":"#ShareBuyback, #ExecutiveAppointments","jir_key_figures":"Upfront payment: 12 million USD\nMilestones: up to 134 million USD\nRoyalties: Tiered\nScope: Exclusive development and commercialization rights for EB05 in Japan\nTiming of impact: To be recorded in consolidated results for the fiscal year ending March 2027","jir_meta_title":"KYORIN Pharmaceutical Co., Ltd. Concludes Exclusive License for EB05 in Japan\uff5cImpact on FY2027 Consolidated Results","jir_meta_description":"KYORIN Pharmaceutical Co., Ltd. has signed an exclusive license agreement with Edesa Biotech for the development and commercialization of EB05 in Japan. The deal includes a 12 million USD upfront payment, up to 134 million USD in milestones, and a royalty structure. The agreement's impact on fiscal year ending March 2027 results is noted.","jir_og_title":"KYORIN Pharmaceutical Co., Ltd. Concludes Exclusive License Agreement for EB05 in Japan","jir_og_description":"KYORIN Pharmaceutical Co., Ltd. has acquired development and commercialization rights in Japan for EB05, an ARDS therapeutic candidate. Terms include an upfront payment, milestones, and royalties. Future development progress is notable.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-145543","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n